Q3 2026 Earnings

November 4, 2026

Versigent

Forward-Looking Statements

This presentation, as well as other statements made by Versigent, contains forward-looking statements that reflect, when made, Versigent's current views with respect to current events, certain investments and acquisitions, business plans and financial performance. Such forward-looking statements are subject to many risks, uncertainties and factors relating to Versigent's operations and business environment, which may cause the actual results of Versigent to be materially different from any future results, expressed or implied, by such forward-looking statements. All statements that address future operating, financial or business performance or Versigent's strategies or expectations are forward-looking statements. In some cases, you can identify these statements by forward-looking words such as "may," "might," "should," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential," "outlook" or "continue," and other comparable terminology. Factors that could cause actual results to differ materially from these forward-looking statements include, but are not limited to, the following: disruptions in the supply of raw materials and other supplies integral to our products; future significant public health crises and other global health crises and the measures taken in response thereto; a prolonged recession and/or a downturn in global automotive sales; the volatile global economic environment and geopolitical conditions, including conditions affecting the credit market and global inflationary pressures; our reliance on relationships with collaborative partners and other third parties for product development and such parties' failure to perform; employee strikes and labor-related disruptions involving us or one or more of our customers affecting our operations; fluctuations in interest rates and foreign currency exchange rates; our failure to comply with the numerous laws and regulations to which we are subject; adverse developments affecting one or more of our suppliers; any adverse impact of legal proceedings and disputes in which we are involved; challenges to our historical and future tax positions by taxing authorities; an increase in our tax burden due to ongoing or future tax audits; our failure to attract and retain key salaried employees and management personnel; our failure to manage the transition to a standalone public company; and our failure to achieve some or all of the benefits expected from our recently completed spin-off. Additional factors are discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Versigent's filings with the Securities and Exchange Commission, including those set forth in the Company's Information Statement furnished with the Company's Registration Statement on Form 10-12B/A filed on March 6, 2026. New risks and uncertainties arise from time to time, and it is impossible for us to predict these events or how they may affect Versigent. It should be remembered that the price of the ordinary shares and any income from them can go down as well as up. Versigent disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events and/or otherwise, except as may be required by law.

Use of Non-GAAP Financial Measures

In addition to its reported results calculated in accordance with accounting principles generally accepted in the United States ("U.S. GAAP"), this presentation also includes non-GAAP financial measures, including Adjusted Net Sales Growth, Adjusted EBITDA, Adjusted Net Income, Adjusted Diluted Earnings Per Share ("Adjusted Diluted EPS"), Adjusted Effective Tax Rate ("Adjusted ETR"), Free Cash Flow, Net Debt and Net Leverage Ratio. Management believes these non-GAAP financial measures, which are defined and discussed in greater detail and reconciled to the most directly comparable U.S. GAAP financial measures in the Appendix, are useful to management, investors, and creditors in their analysis of the Company's financial position, results of operations and liquidity. Management also uses these non-GAAP financial measures for internal planning and forecasting purposes.

Non-GAAP financial measures should not be considered in isolation or as a substitute for our reported results prepared in accordance with U.S. GAAP and, as calculated, may not be comparable to other similarly titled measures of other companies. Refer to the Appendix for further details.

Business Priorities

Unlocking value for shareholders as an independent company

Further strengthen market leading position

- Increase share by leveraging full-service capabilities and best-in-class operating model
- Leverage scale and capabilities in Automotive and other high-value end markets

Continue to optimize cost structure

- Leverage design capabilities and tools to expand automation deployment
- Continue to optimize manufacturing footprint

Consistently deliver strong financial results

- Sustain Automotive growth and strategically augment in target end markets
- Leverage scale for strong Free Cash Flow[1] generation

Deliver incremental value through disciplined capital deployment

- Competitive dividend to shareholders, with excess cash towards share repurchases
- Invest in organic and inorganic growth opportunities

Versigent

(1) Non-GAAP measure. Refer to Appendix for further details.

Q3 2026 Highlights

Delivering Results Through Strong Execution and Operational Discipline Amid Softer Industry Environment

Strong Financial Performance

- Net Sales **+7%** YoY
  - Adjusted Net Sales Growth[1] **+1%** YoY
- Adjusted EBITDA[1] **$275M**, +11% YoY
  - Adjusted EBITDA[1] margin **11.2%**, +40 bps YoY
- Free Cash Flow[1] **$170M**

Commercial Momentum

- **$2.1B** Q3 bookings[2] across new and existing customers
- **55** launches across **21** customers in Q3
- Opened Jiang Cheng R&D and Manufacturing Center (Wuhan, China) – our most advanced, integrated and automated manufacturing facility to date

Adjacent Market Expansion

- Investing in commercial and go-to-market capabilities
- Continued momentum with production launches across key Adjacent Markets:
  - Agriculture (Americas)
  - Commercial Vehicles (Americas, EMEA)

Delivering Shareholder Returns

- **$0.13** quarterly dividend per ordinary share declared
  - First quarterly dividend paid in Sep ‘26
- **$250M** share repurchase authorization available



Versigent

(1) Non-GAAP measure. Refer to Appendix for further details and reconciliation to most directly comparable U.S. GAAP measure.

(2) Bookings represent estimated cumulative net sales associated with customer programs awarded during the period over their expected production lives. Estimates are based on current program content, volume and production life assumptions and are subject to change.

Q3 2026
Financial Results

Q3 2026 Financial Highlights


$ millions, except per share amounts	Q3 2026	Q3 2025	YoY	Commentary
Net Sales *Adjusted Net Sales Growth[1]*	**$2,450**	$2,286	***+7%*** *+1%*	• Reported net sales includes ~500 bps of commodity pass-throughs and ~100 bps of favorable FX • Delivered growth despite lower global automotive production • Volume growth led by Asia Pacific strength
Adjusted EBITDA[1] *Margin*	**$275** *11.2%*	$248 *10.8%*	***+11%*** *+40 bps*	• Reflects strong operational execution amid a significant number of program launches • Includes favorable YoY net pricing • Q3 2026 margin includes ~70 bps net headwind from commodity pass-throughs and FX
Adjusted Diluted EPS[1, 2]	**$1.91**	$1.81	***+6%***	• Q3 2026 net income attributable to Versigent of $102M • Includes higher YoY interest expense due to Q1 2026 debt financing • Adjusted ETR[1] of 22%, compared with 33% in Q3 2025
Free Cash Flow[1]	**$170**	$179	***(5)%***	• Disciplined execution and slightly higher operating cash flow YoY • Higher YoY CapEx supporting elevated launch activity • Includes separation-related costs of $11M, up $4M YoY

(1) Non-GAAP measure. Refer to Appendix for further details and reconciliation to most directly comparable U.S. GAAP measure.

(2) For periods prior to the Spin-Off, the denominator for Adjusted Diluted EPS was calculated using the 70.89 million Versigent ordinary shares outstanding immediately following the Apr 1 '26 Spin-Off.

Q3 Net Sales

$ millions



Regional Net Sales

Americas

		Adjusted*
$1,111M	+6% YoY	+1% YoY

Asia Pacific

		Adjusted*
$868M	+18% YoY	+9% YoY


EMEA

		Adjusted*
$471M	(6)% YoY	(8)% YoY

*Adjusted Net Sales Growth[1]

(1) Non-GAAP measure. Refer to Appendix for further details and reconciliation to most directly comparable U.S. GAAP measure.

Q3 Adjusted EBITDA[1]



(1) Non-GAAP measure. Refer to Appendix for further details and reconciliation to most directly comparable U.S. GAAP measure.

Q3 Free Cash Flow[1] and Financial Position

Free Cash Flow

$ millions	Q3 2026	Q3 2025	YoY
Adjusted EBITDA[1]	**$275**	$248	***$27***
Capital expenditures	(55)	(44)	*(11)*
Separation costs	(11)	(7)	*(4)*
Restructuring payments	(11)	(13)	*2*
Tax payments	(24)	(15)	*(9)*
Interest payments	(15)	–	*(15)*
Working capital & other	11	10	*1*
Free Cash Flow[1]	**$170**	$179	***$(9)***

Financial Position

Strong liquidity and leverage profile as of Sep 30 ’26:

- **$1.5B** total liquidity available
  - **$638M** cash on hand
  - **$850M** revolver undrawn
- Net Leverage Ratio[1] of **1.5x**

Strong Cash Generation and Disciplined Capital Allocation Underpin Financial Strength

(1) Non-GAAP measure. Refer to Appendix for further details and reconciliation to most directly comparable U.S. GAAP measure.

Updated FY 2026 Financial Guidance

$ millions	Current FY 2026	Previous FY 2026 (Aug 4 '26)
Net Sales *Adjusted Net Sales Growth %[1,2]*	**$9,500 – $9,600** *+2%*	*$9,400 – $9,600* *+2%*
Adjusted EBITDA[3]	**$970 – $1,010**	*$950 – $1,030*
Free Cash Flow[3]	**$275 – $325** *Includes ~$70M of separation-related costs*	*$200 – $300* *Includes ~$70M of separation-related costs*

Raised midpoint and tightened Net Sales guidance range on higher commodity pass-throughs

Tightened Adjusted EBITDA[3] guidance range

Raised midpoint and upper end of Free Cash Flow[3] guidance, while tightening range

(1) Forward-looking non-GAAP measure. Refer to Appendix for further details and reconciliation to most directly comparable U.S. GAAP measure.

(2) FY 2026 FX and commodity assumptions as follows: Copper = 6.25/lb, USD/MXN = 17.50, EUR/USD = 1.16, USD/CNY = 6.80.

(3) Forward-looking non-GAAP measure. The Company does not provide a reconciliation of such forward-looking measure to the most directly comparable financial measure calculated and presented in accordance with U.S. GAAP because to do so would be potentially misleading and not practical given the difficulty of projecting event-driven transactional and other non-core operating items in any future period. The magnitude of these items, however, may be significant. Refer to Appendix for definitions of Non-GAAP financial measures.

Capital Allocation

Free Cash Flow[1]

~$1B

Cumulative FCF Generation
2026E to 2028E

Capital Allocation Framework

Capital Expenditures

- Target ~3% of annual net sales

Quarterly Dividend[2]

- $0.13 per share dividend declared on Nov 3 ‘26
  - Record date: Dec 4 ‘26; Payment date: Dec 17 ‘26

Share Repurchases

- $250M share repurchase authorization available

(1) Forward-looking non-GAAP measure. The Company does not provide a reconciliation of such forward-looking measure to the most directly comparable financial measure calculated and presented in accordance with U.S. GAAP because to do so would be potentially misleading and not practical given the difficulty of projecting event-driven transactional and other non-core operating items in any future period. The magnitude of these items, however, may be significant. Refer to Appendix for definitions of Non-GAAP financial measures.

(2) The declaration and payment of future dividends are subject to the discretion of the Company’s Board of Directors and will depend on the Company’s financial condition, results of operations, cash requirements, and other factors deemed relevant by the Board of Directors.

Summary

Building Momentum, Advancing Strategic Priorities

- Executed a significant number of program launches while delivering solid third quarter results
- Demonstrated strength and resilience of our business model amid lower global automotive production and volatile macroeconomic environment
- Guidance updates underscore confidence in our underlying performance and outlook
- Building commercial and go-to-market capabilities to unlock growth in Adjacent Markets



Versigent

Appendix

Supplemental Information

Non-GAAP Financial Measures (unaudited)

In addition to its reported results calculated in accordance with U.S. GAAP, the Company has included in this presentation Adjusted Net Sales Growth, Adjusted EBITDA, Adjusted Net Income, Adjusted Diluted EPS and Adjusted ETR, performance measures, and Free Cash Flow, Net Debt and Net Leverage Ratio, liquidity measures, each of which the Securities and Exchange Commission defines as a "non-GAAP financial measure". Management believes these non-GAAP financial measures, when read in conjunction with the Company's reported results, calculated in accordance with U.S. GAAP, provide investors with useful supplemental information regarding the Company's ongoing financial performance and liquidity and enhance comparability between periods by excluding certain items that management believes are not indicative of the Company's core operating performance or may obscure underlying business results and trends. In addition, management believes that Free Cash Flow, Net Debt and Net Leverage Ratio are meaningful measures of financial condition as they are commonly used by management, investors, and creditors to assess capital structure risk. Management also uses these measures for internal reporting, financial decision-making, planning and forecasting, evaluating performance and liquidity, and determining appropriate capital allocation strategies, as applicable.

The Company's definitions and calculations, as set forth in the reconciliations of Adjusted Net Sales Growth, Adjusted EBITDA, Adjusted Net Income, Adjusted Diluted EPS, Adjusted ETR, Free Cash Flow, Net Debt and Net Leverage Ratio included herein, may not be comparable to similarly titled measures used by other companies because other companies may not calculate them in the same manner as the Company does. These non-GAAP financial measures should not be viewed in isolation from, nor as alternatives to, net sales, net income (loss) attributable to Versigent, diluted earnings per share ("diluted EPS"), net cash provided by (used in) operating activities and total debt, as applicable, calculated in accordance with U.S. GAAP.

The Company does not provide a reconciliation of forward-looking Adjusted EBITDA to net income (loss) attributable to Versigent and Free Cash Flow to net cash provided by (used in) operating activities, the most directly comparable financial measures calculated and presented in accordance with U.S. GAAP because to do so would be potentially misleading and not practical given the difficulty of projecting event-driven transactional and other non-core operating items in any future period. The magnitude of these items, however, may be significant.

Adjusted Net Sales Growth is defined as the change in reported net sales relative to the comparable period, excluding the impact on net sales from foreign currency and commodity movements.

Adjusted EBITDA is defined as net income (loss) attributable to Versigent before depreciation and amortization (including asset impairments), interest expense, income tax expense (benefit), net income (loss) attributable to noncontrolling interest, other expense (income), net, equity income (loss), net of tax, restructuring, separation costs related to the Spin-Off, other acquisition and portfolio project costs (which includes costs incurred to integrate acquired businesses and to plan and execute product portfolio transformation actions, including business and product acquisitions and divestitures) and other special items. Adjusted EBITDA margin represents Adjusted EBITDA as a percentage of net sales**.**

Adjusted Net Income represents net income (loss) attributable to Versigent before amortization, restructuring, separation costs related to the Spin-Off, other acquisition and portfolio project costs (which includes costs incurred to integrate acquired businesses and to plan and execute product portfolio transformation actions, including business and product acquisitions and divestitures) and other special items, including the tax impact thereon.

Adjusted Diluted EPS is defined as Adjusted Net Income divided by the weighted average number of diluted shares outstanding for the period.

Adjusted ETR is calculated as income tax expense (benefit), adjusted for the tax impact of the adjusting items used to calculate Adjusted Net Income, divided by income before income taxes and equity income, adjusted for those same items.

Free Cash Flow is defined as net cash provided by (used in) operating activities less capital expenditures. The calculation of Free Cash Flow does not reflect cash used to service debt, pay dividends or repurchase shares and therefore, does not necessarily reflect funds available for investment or other discretionary uses.

Net Debt is defined as total debt less cash and cash equivalents.

Net Leverage Ratio is defined as Net Debt divided by the trailing 12 months of Adjusted EBITDA.

YTD Results


$ millions, except per share amounts	YTD 2026	YTD 2025	YoY
Net Sales	**$7,106**	$6,516	***+9%***
Adjusted Net Sales Growth[1]			*+3%*
Adjusted EBITDA[1]	**$750**	$664	***+13%***
Margin	*10.6%*	*10.2%*	*+40 bps*
Adjusted Diluted EPS[1, 2]	**$5.90**	$5.30	***+11%***
Free Cash Flow[1]	**$247**	$290	***(15)%***

(1) Non-GAAP measure. Refer to Supplemental Information included herein for further details and reconciliation to most directly comparable U.S. GAAP measure.

(2) For periods prior to the Spin-Off, the denominator for Adjusted Diluted EPS was calculated using the 70.89 million Versigent ordinary shares outstanding immediately following the Apr 1 '26 Spin-Off.

YTD Net Sales

$ millions



Regional Net Sales

Americas

$3,170M | +9% YoY | Adjusted* +4% YoY

Asia Pacific

$2,432M | +19% YoY | Adjusted* +12% YoY


EMEA

$1,504M | (4)% YoY | Adjusted* (10)% YoY

*Adjusted Net Sales Growth[1]

(1) Non-GAAP measure. Refer to Supplemental Information included herein for further details and reconciliation to most directly comparable U.S. GAAP measure.

YTD Adjusted EBITDA[1]



(1) Non-GAAP measure. Refer to Supplemental Information included herein for further details and reconciliation to most directly comparable U.S. GAAP measure.

YTD Free Cash Flow[1]

$ millions	YTD 2026	YTD 2025	YoY
Adjusted EBITDA[1]	**$750**	$664	***$86***
Capital expenditures	(172)	(123)	*(49)*
Separation costs	(59)	(14)	*(45)*
Restructuring payments	(48)	(41)	*(7)*
Tax payments	(74)	(72)	*(2)*
Interest payments	(18)	(2)	*(16)*
Working capital & other	(132)	(122)	*(10)*
Free Cash Flow[1]	**$247**	$290	***$(43)***

(1) Non-GAAP measure. Refer to Supplemental Information included herein for further details and reconciliation to most directly comparable U.S. GAAP measure.

Reconciliation of Net Sales to Adjusted Net Sales Growth

		Q3 2026	YTD 2026
Global	Reported net sales YoY % change	7%	9%
	Less: impact of foreign currency movements	(1)%	(2)%
	Less: impact of commodity movements	(5)%	(4)%
	Adjusted Net Sales Growth	**1%**	**3%**
Americas	Reported net sales YoY % change	6%	9%
	Less: impact of foreign currency and commodity movements	(5)%	(5)%
	Adjusted Net Sales Growth	**1%**	**4%**
Asia Pacific	Reported net sales YoY % change	18%	19%
	Less: impact of foreign currency and commodity movements	(9)%	(7)%
	Adjusted Net Sales Growth	**9%**	**12%**
EMEA	Reported net sales YoY % change	(6)%	(4)%
	Less: impact of foreign currency and commodity movements	(2)%	(6)%
	Adjusted Net Sales Growth	**(8)%**	**(10)%**

		FY 2026 Guidance Midpoint
Global	Reported net sales YoY % change	8%
	Less: impact of foreign currency and commodity movements	(6)%
	Adjusted Net Sales Growth	**2%**

Reconciliation of Net Income Attributable to Versigent to EBITDA and Adjusted EBITDA and Net Leverage Ratio

$ millions	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026	TTM Sep 2026	YTD 2026	YTD 2025
Net income attributable to Versigent	109	217	78	118	102	515	298	311
Interest expense[1]	–	–	5	36	36	77	77	3
Income tax expense (benefit)	54	(110)	(9)	46	35	(38)	72	104
Net income (loss) attributable to noncontrolling interest	4	8	3	(2)	10	19	11	10
Depreciation and amortization	55	61	61	51	55	228	167	166
EBITDA	**222**	**176**	**138**	**249**	**238**	**801**	**625**	**594**
Other expense, net[1]	–	3	1	6	2	12	9	1
Equity income, net	(3)	(2)	(4)	(5)	–	(11)	(9)	(11)
Restructuring	21	24	46	–	22	92	68	62
Separation costs and other special items	7	28	26	22	11	87	59	14
Net loss (gain) on lease terminations	–	–	(4)	–	2	(2)	(2)	–
Other acquisition and portfolio project costs	1	–	–	–	–	–	–	4
Adjusted EBITDA	**248**	**229**	**203**	**272**	**275**	**979**	**750**	**664**
Total debt						2,124		
Less: cash and cash equivalents						(638)		
Net Debt						**1,486**		
Net Leverage Ratio						**1.5x**		
Memo:								
Net sales	2,286	2,302	2,212	2,444	2,450	9,408	7,106	6,516
Net income margin	*4.8%*	*9.4%*	*3.5%*	*4.8%*	*4.2%*	*5.5%*	*4.2%*	*4.8%*
Adjusted EBITDA margin	*10.8%*	*9.9%*	*9.2%*	*11.1%*	*11.2%*	*10.4%*	*10.6%*	*10.2%*

(1) Prior period amounts were reclassified to conform to the presentation adopted in Q2 2026.

Reconciliation of Net Income Attributable to Versigent to Adjusted Net Income and Adjusted Diluted EPS

$ millions, except per share amounts	Q3 2026	Q3 2025	YTD 2026	YTD 2025
Net income attributable to Versigent	102	109	298	311
Adjusting items:				
Amortization	–	–	1	1
Restructuring	22	21	68	62
Separation costs	11	7	59	14
Other acquisition and portfolio project costs	–	1	–	4
Asset impairments	7	–	14	3
Net loss (gain) on lease terminations	2	–	(2)	–
Pension curtailment and settlement losses	1	–	7	–
Separation-related interest expense	–	–	2	–
Total adjusting items	43	29	149	84
Tax impact of adjusting items[1]	(7)	(10)	(24)	(19)
Adjusted Net Income	**138**	**128**	**423**	**376**
Weighted average number of diluted shares outstanding[2]	72.25	70.89	71.67	70.89
Diluted EPS attributable to Versigent	1.41	1.54	4.16	4.39
Adjusted Diluted EPS	**1.91**	**1.81**	**5.90**	**5.30**

(1) Represents the income tax impacts of the adjustments made for amortization, restructuring and other special items by calculating the income tax impact of these items using the appropriate tax rate for the jurisdiction where the charges were incurred.

(2) For periods prior to the Spin-Off, the denominator for diluted EPS and Adjusted Diluted EPS was calculated using the 70.89 million Versigent ordinary shares outstanding immediately following the Apr 1 '26 Spin-Off.

Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow

$ millions	Q3 2026	Q3 2025	YTD 2026	YTD 2025
Net cash provided by operating activities	225	223	419	413
Capital expenditures	(55)	(44)	(172)	(123)
Free Cash Flow	**170**	**179**	**247**	**290**

Reconciliation of Effective Tax Rate to Adjusted ETR

$ millions	Q3 2026	Q3 2025	YTD 2026	YTD 2025
Income before income taxes and equity income	147	164	372	414
Plus: impact of adjusting items[1]	43	29	149	84
Adjusted Income Before Income Taxes and Equity Income	**190**	**193**	**521**	**498**
Income tax expense	(35)	(54)	(72)	(104)
Plus: tax impact of adjusting items[1]	(7)	(10)	(24)	(19)
Adjusted Income Tax Expense	**(42)**	**(64)**	**(96)**	**(123)**
Effective Tax Rate	**24%**	**33%**	**19%**	**25%**
Adjusted ETR	**22%**	**33%**	**18%**	**25%**

(1) Refer to "Reconciliation of Net Income Attributable to Versigent to Adjusted Net Income and Adjusted Diluted EPS" included herein for further details regarding adjusting items and tax impact of adjusting items.



Versigent